Boston Scientific
BSX
#197
Rank
$71.90 B
Marketcap
$50.03
Share price
0.87%
Change (1 day)
12.96%
Change (1 year)
Categories

Boston Scientific Corporation is an American medical device manufacturer. The company offers solutions for the following medical specialties: electrophysiology, gastroenterology, vascular surgery, gynecology, interventional cardiology, interventional radiology, female pelvic medicine, neurological surgery, orthopedic surgery, pulmology, pain medicine, structural heart, urology.

P/E ratio for Boston Scientific (BSX)

P/E ratio as of April 2023 (TTM): 111

According to Boston Scientific's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 111.111. At the end of 2021 the company had a P/E ratio of 61.6.

P/E ratio history for Boston Scientific from 2001 to 2022

PE ratio at the end of each year

Year P/E ratio Change
202161.6-120.55%
2020-300-2339.26%
201913.4-54.19%
201829.2-90.57%
2017310272.48%
201683.2-181.55%
2015-102-256.32%
201465.3-145.46%
2013-1446889.85%
2012-2.05

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
26.4-76.24%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
33.7-69.64%๐Ÿ‡บ๐Ÿ‡ธ USA
45.8-58.81%๐Ÿ‡บ๐Ÿ‡ธ USA
32.7-70.61%๐Ÿ‡บ๐Ÿ‡ธ USA
56.5-49.19%๐Ÿ‡บ๐Ÿ‡ธ USA
-12.5-111.21%๐Ÿ‡บ๐Ÿ‡ธ USA
-37.6-133.83%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.